We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Stool Test Could Better Detect COVID-19 than Traditional Nose Swabs Due to Prolonged Gut Viral Infection

By LabMedica International staff writers
Posted on 08 Sep 2020
Researchers have found for the first time that COVID-19 patients have active and prolonged gut viral infection, suggesting that stool tests could be more safe, accurate and non-invasive than traditional nose swabs in detecting coronavirus.

Researchers from the Faculty of Medicine of The Chinese University of Hong Kong (Sha Tin District, Hong Kong) found that COVID-19 patients have active and prolonged gut viral infection, even in the absence of gastrointestinal (GI) symptoms. More...
After respiratory clearance of coronavirus, the activity of viral infection and replication still persists in the gut. To better understand the activity and infectivity of COVID-19 virus in the GI tract during the disease’s course, the researchers investigated the stool samples of 15 COVID-19 patients in Hong Kong. The researchers found that there was active gut viral infection in seven patients even in the absence of GI symptoms. Three patients continued to display active viral infection up to six days after clearance of the virus from their respiratory samples. The researchers also found that gut microbiota of patients with high SARS-CoV-2 infectivity were characterized by enrichment of pathogens and loss of “good” bacteria that are capable of producing short-chain fatty acid.

Earlier studies have found that the COVID-19 virus was detectable in the stool samples of all patients, regardless of the degree of illness. The researchers undertook screening of more than 128 stool samples of Hong Kong airport arrivals that revealed six children with confirmed COVID-19 infection and a detection rate of 0.28%. The researchers believe that stool screening test can help identify asymptomatic people carrying the COVID-19 virus as early as possible in order to stop its spread in the community.

“The viral load in the stool of infant and children is many times higher than that in adults, and could be equivalent to that of adult respiratory samples,” said Professor Paul Kay Sheung CHAN, Chairman of the Department of Microbiology and Associate Director of the Centre for Gut Microbiota Research. “The activity of viral infection and replication also persist longer in the guts of infant and children. Stool specimens are more convenient, safe and non-invasive to collect in the paediatric population and can give accurate results. This makes stool test a better option for COVID-19 screening in babies, young children and those whose respiratory samples are difficult to collect.”

Related Links:
The Chinese University of Hong Kong


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Microscope
dIFine
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.